Primary Investigators: William Gillanders, MD, and Robert Schreiber, PhD
T-cell infiltration (pink) into PDAC Project 4 aims to develop and test personalized vaccines for pancreatic ductal adenocarcinoma (PDAC) patients based on their genetic makeup. Our investigators' previous research has shown that neoantigens are important tumor rejection toxins in the body and, thus, will help in the development of a personalized vaccine for PDAC patients. In the creation of this proposed vaccine, our investigators will test the success rate in clinical trials. Based on the results, the stage will be set for future clinical trials for personalized vaccines and/or combination therapies.
Research Overview of Project 4